*Optimal dilutions/concentrations should be determined by the researcher.
|1:5000 - 1:10000
|1:5000 - 1:10000
|1:50 - 1:200
Not tested in other applications.
Typically less than 1% cross reactivity against other types of apoLipoprotein was detected by ELISA against purified standards. This antibody reacts with human apoLipoprotein C-I and has negligible cross-reactivity with Type A-I, A-II, B, C-II, C-III, E and J apoLipoproteins. Specific cross reaction of anti-apoLipoprotein antibodies with antigens from other species has not been determined. Non-specific cross reaction of anti-apoLipoprotein antibodies with other human serum proteins is negligible.
0.125 M Sodium Borate, 0.075 M Sodium Chloride, 0.005 M EDTA, pH 8.0 and 0.01% (w/v) Sodium Azide
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
1.0 mg/ml (Please refer to the vial label for the specific concentration.)
Apolipoprotein CI produced synthetically in full-length form (not selected epitopes) using conventional peptide technology.
Purified by antigen-affinity chromatography.
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
At least 9 distinct polymorphic forms of apolipoproteins are known. The apolipoproteins act as stabilizers of the intact lipoprotein particles. Quantitative measurements of HDL, LDL and VLDL particles in human serum are often used to estimate an individuals' relative risk of coronary heart disease. In addition, quantitative immunological measurements of certain apolipoproteins (especially A-1 and B) have been suggested to be more accurate estimators of coronary heart disease than measurements of lipoprotein particles (especially HDL and LDL). The apolipoproteins are derived from human plasma by density gradient ultracentrifugation and HPLC.